Promotor: Prof.dr. T. Hankemeier, Prof.dr. J.C.T. Eijkel (Twente University)

Promotor: Prof.dr. T. Hankemeier, Co-Promotor: R.J. Vreeken

How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…

Assistant Professor at the Metabolomics group, LUMC, The Nederlands

The Division of Systems Pharmacology and Pharmacy (SPP) aims to develop precision medicine approaches to characterize and predict variation in treatment response and enhance translational drug development strategies.

Can we develop a generic method for Quan/Qual analysis of small molecule drugs, their metabolites and endogenous metabolites in (pre-)clinical samples?

A new research line is the development of liquid biopsy fingerprints to predict early Alzheimer’s disease (AD) stage in human in readily accessible body fluids in human (in collaboration with: Dr. Geert-Jan Groeneveld, CHDR; Prof. Elga de Vries, Free University Medical Center; and others).

The Biomedical Microscale Analytics group is led by Dr. Rawi Ramautar. In present-day metabolomics, and bioanalysis in general, the analytical toolbox used encounters difficulties for the analysis of limited amounts of biological samples. As a result, a significant number of crucial biomedical/clinical…

Development of micro-scale analytical tools to be used to address relevant biomedical questions in the field of neuroscience, and other application areas intrinsically dealing with small sample amounts.

Symposium

An overview of research projects at the Predictive Pharmacology group.